Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer
Background: Most patients with small-cell lung cancer (SCLC) experience disease progression after first-line chemotherapy. Notably, nab-paclitaxel monotherapy has antitumor activity in relapsed SCLC. Objective: This study evaluated the efficacy and safety of combined of nab-paclitaxel and immune che...
| Egile Nagusiak: | , , , , , |
|---|---|
| Formatua: | Artikulua |
| Hizkuntza: | English |
| Argitaratua: |
SAGE Publishing
2023-06-01
|
| Saila: | Therapeutic Advances in Medical Oncology |
| Sarrera elektronikoa: | https://doi.org/10.1177/17588359231179315 |